With the expansion of oral treatment options, adherence is also becoming a stronger driver in prescribing decisions. The competitive landscape for PNH has seen significant shifts, particularly ...

Ilene C. Wetiz, MD, professor of clinical medicine at the Keck School of Medicine at the University of Southern California, discusses the treatment options for this case: So, what are the ...

Teva and Samsung Bioepis have launched Epysqli, a cost-saving Soliris biosimilar, offering a 30% discount and new hope for ...

"But the point is that we have multiple options that we can offer patients who continue to have anemia despite treatment with C5 inhibitors." Shammo also encouraged patients with PNH to seek out ...

Along with haemolysis, people with PNH can suffer life-threatening blood ... so there's a clear need for new treatment options, according to Prof Jun Ho Jang of Sungkyunkwan University in South ...

so there’s a clear need for new treatment options. The FDA approval is based on the APPLY-PNH and APPOINT-PNH trials, which showed that the drug was able to achieve “clinically meaningful ...

discusses the selected treatment and the results of the case: So, what happened to this patient? Well, we started her on a C5 inhibitor because she had a very large PNH clone. You can see on the ...

with growing consensus that all PNH patients should be on a complement or factor inhibitor, regardless of disease burden. With the expansion of oral treatment options, adherence is also becoming a ...